ଡୁଲୋକ୍ସେଟିନ

ଡୁଲୋକ୍ସେଟିନ
Clinical data
Trade names	Cymbalta, others
AHFS/Drugs.com	monograph
MedlinePlus	a604030
data	EU EMA: yes; US FDA: duloxetine;
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Drug class	Serotonin–norepinephrine reuptake inhibitor
ATC code	N06AX21 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	~ 50% (32% to 80%)
Protein binding	~ 95%
Metabolism	Liver, two P450 isozymes, CYP2D6 and CYP1A2
Elimination half-life	12 hours
Excretion	70% in urine, 20% in feces
Identifiers
	IUPAC name (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine;
CAS Number	116539-59-4 ; as HCl: 136434-34-9 ;
PubChem CID	60835;
IUPHAR/BPS	202;
DrugBank	DB00476 ;
ChemSpider	54822 ;
UNII	O5TNM5N07U; as HCl: 9044SC542W ;
KEGG	D07880 ;
ChEBI	CHEBI:36795 ;
ChEMBL	CHEMBL1175 ;
PDB ligand	29E (PDBe, RCSB PDB);
ECHA InfoCard	100.116.825
Chemical and physical data
Formula	C18H19NOS
Molar mass	297.41456 g/mol
3D model (JSmol)	Interactive image;
	SMILES CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32;
	InChI InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1 ; Key:ZEUITGRIYCTCEM-KRWDZBQOSA-N ;
(what is this?) (verify)

ଡୁଲୋକ୍ସେଟିନ (ଇଂରାଜୀ ଭାଷାରେ Duloxetine, ଏକ ବ୍ୟବସାୟୀକ ନାମ ସିମ୍ବାଲ୍ଟା/ Cymbalta)^[୧] ଏକ ଔଷଧ ଯାହା ପ୍ରମୁଖ ଅବସାଦ ବେମାରୀ, ଜେନେରାଲାଇଜଡ ଆଙ୍ଗଜାଇଟି ଡିଜଅର୍ଡ଼ର (generalized anxiety disorder), ଫାଇବ୍ରୋମ୍ୟାଲ୍‌ଜିଆ, ଓ ନିଉରୋପାଥିକ ଯନ୍ତ୍ରଣା (neuropathic pain) ଚିକିତ୍ସା ନିମନ୍ତେ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ଡୁଲୋକ୍ସେଟିନର ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଶୁଷ୍କ ପାଟି, ଅଇ, ଥକ୍କାଣ ଅନୁଭବ, ମୁଣ୍ଡ ଓଜନିଆ, ଉତ୍ତେଜନା, ଯୌନ ସମସ୍ୟା ଓ ଅଧିକ ସ୍ୱେଦ ନିର୍ଗତ ହୁଏ ।^[୨] ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ସାଂଘାତିକ ହେଲେ ଆତ୍ମହତ୍ୟା ସଙ୍କଟ, ସେରୋଟୋନିନ ସିଣ୍ଡ୍ରୋମ, ମାନିଆ (mania), ଓ ଯକୃତ ସମସ୍ୟ (liver problems) ହୋଇପାରେ ।^[୨] ଏହି ଔଷଧ ବନ୍ଦ କରିଦେଲେ ଆଣ୍ଟିଡିପ୍ରେସାଣ୍ଟ ଉଇଥଡ୍ରଆଲ ସିଣ୍ଡ୍ରୋମ (Antidepressant withdrawal syndrome) ସୃଷ୍ଟି ହୋଇପାରେ । ^[୨] ଗର୍ଭାବସ୍ଥାର ଶେଷ ଭାଗରେ ଏହା ଶିଶୁର କ୍ଷତି କରିପାରେ ।^[୨] ଏହା ଏକ ସେରୋଟୋନିନ-ନରଏପିନେଫ୍ରିନ ରିଅପଟେକ ଇନହିବିଟର (serotonin–norepinephrine reuptake inhibitor) ଔଷଧ ।^[୩] ଏହାର କାର୍ଯ୍ୟବିଧି ଅଦ୍ୟାବଧି ସ୍ପଷ୍ଟ ହୋଇନାହିଁ । ^[୨]

ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସନ ୨୦୦୪ରେ ଡୁଲୋକ୍ସିଟିନ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୨] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ (generic medication) ବିକ୍ରୟ ହୁଏ ।^[୩] ସନ ୨୦୧୮ରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ଡୋଜର ହୋଲସେଲ ମୂଲ୍ୟ ୦.୨୦ ଆମେରିକୀୟ ଡଲାର ଥିଲା ।^[୪] ସନ ୨୦୧୬ରେ ଏହାର ୧୫ ନିୟୁତ ପ୍ରେସକ୍ରିପସନ ହୋଇ ସର୍ବାଧିକ ପ୍ରେସକ୍ରିପସନ ତାଲିକାରେ ୪୮ତମ ସ୍ଥାନ ଅଧିକାର କରିଥିଲା । ^[୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Duloxetine". Drugs.com (in ଇଂରାଜୀ). Retrieved 24 December 2018.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Duloxetine". Monograph. The American Society of Health-System Pharmacists. Retrieved 2018-12-24.
↑ ^୩.୦ ^୩.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 364–365. ISBN 9780857113382.
↑ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2018-12-19. Retrieved 22 December 2018.
↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

ବାହ୍ୟ ଲିଙ୍କ

[generics-1] ୧.୦ ^୧.୧ "Duloxetine". Drugs.com (in ଇଂରାଜୀ). Retrieved 24 December 2018.

[AHFS2018-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Duloxetine". Monograph. The American Society of Health-System Pharmacists. Retrieved 2018-12-24.

[BNF76-3] ୩.୦ ^୩.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 364–365. ISBN 9780857113382.

[4] "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2018-12-19. Retrieved 22 December 2018.

[5] "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[୧]

[୨]

[୩]

[୪]

[୫]

Clinical data


Trade names	Cymbalta, others^[୧]
AHFS/Drugs.com	monograph
MedlinePlus	a604030
data	EU EMA: yes US FDA: duloxetine
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	By mouth
Drug class	Serotonin–norepinephrine reuptake inhibitor
ATC code	N06AX21 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	~ 50% (32% to 80%)
Protein binding	~ 95%
Metabolism	Liver, two P450 isozymes, CYP2D6 and CYP1A2
Elimination half-life	12 hours
Excretion	70% in urine, 20% in feces
Identifiers
IUPAC name (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
CAS Number	116539-59-4^N as HCl: 136434-34-9^N
PubChem CID	60835
IUPHAR/BPS	202
DrugBank	DB00476^Y
ChemSpider	54822^Y
UNII	O5TNM5N07U as HCl: 9044SC542W^N
KEGG	D07880^Y
ChEBI	CHEBI:36795^Y
ChEMBL	CHEMBL1175^Y
PDB ligand	29E (PDBe, RCSB PDB)
ECHA InfoCard	100.116.825
Chemical and physical data
Formula	C₁₈H₁₉NOS
Molar mass	297.41456 g/mol
3D model (JSmol)	Interactive image
SMILES CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
InChI InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1^Y Key:ZEUITGRIYCTCEM-KRWDZBQOSA-N^Y
^NY (what is this?) (verify)